NASDAQ:IMNN Imunon (IMNN) Stock Price, News & Analysis $1.15 -0.02 (-1.71%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$1.10▼$1.1950-Day Range$1.06▼$1.5352-Week Range$0.48▼$2.00Volume129,025 shsAverage Volume119,453 shsMarket Capitalization$10.81 millionP/E RatioN/ADividend YieldN/APrice Target$12.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsShort InterestTrends Get Imunon alerts: Email Address Imunon MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside943.5% Upside$12.00 Price TargetShort InterestHealthy2.99% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.44Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($2.09) to ($1.64) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.16 out of 5 starsMedical Sector378th out of 936 stocksPharmaceutical Preparations Industry179th out of 436 stocks 3.5 Analyst's Opinion Consensus RatingImunon has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageImunon has only been the subject of 1 research reports in the past 90 days.Read more about Imunon's stock forecast and price target. Previous Next 4.0 Short Interest Percentage of Shares Shorted2.99% of the float of Imunon has been sold short.Short Interest Ratio / Days to CoverImunon has a short interest ratio ("days to cover") of 7.9.Change versus previous monthShort interest in Imunon has recently decreased by 18.56%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldImunon does not currently pay a dividend.Dividend GrowthImunon does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for IMNN. Previous Next 4.1 News and Social Media Coverage News SentimentImunon has a news sentiment score of 1.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Imunon this week, compared to 1 article on an average week.Search Interest4 people have searched for IMNN on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat Follows1 people have added Imunon to their MarketBeat watchlist in the last 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Imunon insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.00% of the stock of Imunon is held by insiders.Percentage Held by InstitutionsOnly 4.47% of the stock of Imunon is held by institutions.Read more about Imunon's insider trading history. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Imunon are expected to grow in the coming year, from ($2.09) to ($1.64) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Imunon is -0.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Imunon is -0.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioImunon has a P/B Ratio of 0.81. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Imunon's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto Swap Profits625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here About Imunon Stock (NASDAQ:IMNN)Imunon, Inc., a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company's lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development. Its preclinical stage products include IMNN-101, a COVID-19 booster vaccine; IMNN-102 for the treatment of Lassa virus; and IMNN-201, a Trp2 tumor associated antigen cancer vaccine in melanoma. In addition, the company develops non-viral DNA technology across four modalities, such as TheraPlas for the coding of proteins and cytokines in the treatment of solid tumors; PlaCCine for the coding of viral antigens that can elicit a strong immunological response; FixPlas for the application of Imunon's DNA technology to produce universal cancer vaccines; and IndiPlas, which is in the discovery phase for the development of personalized cancer vaccines or neoepitope cancer vaccines. Imunon, Inc. was formerly known as Celsion Corporation and changed its name to Imunon, Inc. in September 2022. The company was founded in 1982 and is headquartered in Lawrenceville, New Jersey.Read More IMNN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart IMNN Stock News HeadlinesJune 24, 2024 | globenewswire.comIMUNON Announces Database Lock for Phase 2 OVATION 2 Study with IMNN-001 in Advanced Ovarian CancerJune 5, 2024 | globenewswire.comFirst Participants Vaccinated in IMUNON's IMNN-101 Phase 1 Clinical TrialJuly 26, 2024 | Traders Agency (Ad)top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.May 16, 2024 | finance.yahoo.comIMNN: Results from OVATION 2 Study in Mid-2024…May 15, 2024 | uk.finance.yahoo.comQ1 2024 Imunon Inc Earnings CallMay 15, 2024 | finance.yahoo.comAbstract on Phase 2 Study with IMUNON’s IMNN-001 Plus Bevacizumab Accepted for Presentation at the American Society of Clinical Oncology Annual MeetingMay 15, 2024 | globenewswire.comAbstract on Phase 2 Study with IMUNON's IMNN-001 Plus Bevacizumab Accepted for Presentation at the American Society of Clinical Oncology Annual MeetingMay 14, 2024 | msn.comImunon, Inc. (NASDAQ:IMNN) Q1 2024 Earnings Call TranscriptJuly 26, 2024 | Traders Agency (Ad)top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.May 14, 2024 | uk.finance.yahoo.comImunon Inc (IMNN) Q1 2024 Earnings Call Transcript Highlights: Strategic Developments and ...May 13, 2024 | msn.comImunon GAAP EPS of -$0.52 beats by $0.05May 13, 2024 | globenewswire.comIMUNON Announces Site Activation for IMNN-101 Phase 1 Vaccine StudyMay 13, 2024 | globenewswire.comIMUNON Reports First Quarter 2024 Financial Results and Provides Business UpdateMay 8, 2024 | globenewswire.comIMUNON Appoints Director Dr. Stacy R. Lindborg as President and CEOMay 6, 2024 | globenewswire.comIMUNON to Hold First Quarter 2024 Financial Results and Business Update Conference Call on Monday, May 13, 2024April 28, 2024 | finance.yahoo.comImunon, Inc. (IMNN)April 18, 2024 | finance.yahoo.comIMUNON’s IND Application Cleared to Begin Human Testing of IMNN-101April 18, 2024 | globenewswire.comIMUNON's IND Application Cleared to Begin Human Testing of IMNN-101See More Headlines Receive IMNN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Imunon and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/13/2024Today7/26/2024Next Earnings (Estimated)8/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:IMNN CUSIPN/A CIK749647 Webwww.imunon.com Phone(609) 896-9100Fax609-896-2200Employees30Year FoundedN/APrice Target and Rating Average Stock Price Target$12.00 High Stock Price Target$12.00 Low Stock Price Target$12.00 Potential Upside/Downside+943.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($2.02) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-19,510,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-122.68% Return on Assets-84.15% Debt Debt-to-Equity RatioN/A Current Ratio2.51 Quick Ratio2.51 Sales & Book Value Annual Sales$500,000.00 Price / Sales21.62 Cash FlowN/A Price / Cash FlowN/A Book Value$1.42 per share Price / Book0.81Miscellaneous Outstanding Shares9,400,000Free Float8,931,000Market Cap$10.81 million OptionableNot Optionable Beta2.12 The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesMr. Michael H. Tardugno (Age 73)Executive Chairman Dr. Khursheed Anwer M.B.A. (Age 64)Ph.D., Executive VP & Chief Scientific Officer Comp: $632.26kMr. Timothy J. Tumminello CPA (Age 66)Chief Accounting Officer & Controller Comp: $108.31kDr. Sebastien Hazard M.D. (Age 52)Executive VP & Chief Medical Officer Key CompetitorsLakeshore BiopharmaNASDAQ:LSBYS BiopharmaNASDAQ:YSBioXcel TherapeuticsNASDAQ:BTAIProMIS NeurosciencesNASDAQ:PMNIN8bioNASDAQ:INABView All Competitors IMNN Stock Analysis - Frequently Asked Questions How have IMNN shares performed this year? Imunon's stock was trading at $0.68 at the start of the year. Since then, IMNN shares have increased by 69.1% and is now trading at $1.15. View the best growth stocks for 2024 here. How were Imunon's earnings last quarter? Imunon, Inc. (NASDAQ:IMNN) announced its quarterly earnings data on Monday, May, 13th. The company reported ($0.52) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.57) by $0.05. How do I buy shares of Imunon? Shares of IMNN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:IMNN) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredMust-See: Elon’s New Invention is Absolutely InsaneCould Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredElon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” ...Porter & Company | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Imunon, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Imunon With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free IMNN Stock Alerts